Natus Medical has achieved a deal worth $1.2 billion offered by France-based ArchiMed Group. The deal would remove Natus Medical from public trading, NASDAQ. It had gone public in July 2001 with a $55 million initial public offering. Following its exit, the shareholders of the company will receive $33.50 in cash. The deal would be completed by the third quarter of this year.
Natus Medical was founded in the 1980s in Wisconsin. It offered a wide variety of software and medical devices in the areas of hearing aid, neurological care and newborn care. The current CEO of the startup is Thomas Sullivan. Post this acquisition, Natus Medical will continue to cater to the patients affected by brain disorders and the eight sensory nervous systems.
Natus Medical has so far acquired five organisations. In 2006, they acquired Deltamed S.A. This was followed by Hawaii Medical in 2009. In the same year, they also acquired Alpine Biomed. Later, in 2013, they acquired Grass Technologies Product Group. Their latest acquisition was of RetCam Ophthalmic Imaging System in 2016.
ArchiMed on the other hand has acquired 21 organisations. This includes Direct Healthcare Group, ActiGraph, NAMSA, Stragen, Suanfarma Biotech, Xpress Biologics, Cube Biotech, Cardioline, CARSO Group and the latest addition Natus Medical.